News

Posts are organized into categories for ease of navigation:

• Algorithm - developments to the interpretation algorithm implemented in Python.
• Announcement - general news related to the Molecular Oncology Almanac.
• Database - changes and additions to the underlying knowledge base.
• Release - aggregated release notes from GitHub releases (serving as the project changelog).

• Database release 2023-12-07 Categories:  Database, Release

  Added entries:

  • (FDA) PIK3CA and AKT somatic variants and PTEN loss of function variants and sensitivity to capivasertib in combination with fulvestrant for patients with breast cancer.
  • (FDA) ROS1 rearrangements and sensitivity to repotrectinib in patients with nsclc.
  Continue reading
• Database release 2023-11-09 Categories:  Database, Release

  This month’s data release features recent FDA approvals, updates of mutational signatures from version 2 to 3.4, updates to the source fields for several citations, removal of several entries, revising format of all clinical guideline citations, and the publication_date field has been populated for all current database records.

  Continue reading
• Database release 2023-10-05 Categories:  Database, Release

  Added entries:

  • (Preclinical) ATM copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) BAP1 copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) BARD1 copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) CCNE1 copy number amplifications and sensitivity to dinaciclib in osteosarcoma.
  • (Preclinical) CDK4 copy number amplifications and sensitivity to palbociclib in osteosarcoma.
  • (Preclinical) CHEK2 copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) FANCA copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) FGFR1 copy number amplifications and sensitivity to AZ4547 and PD173074 in osteosarcoma.
  • (Preclinical) MYC copy number amplifications and sensitivity to AT7519 in osteosarcoma.
  • (Preclinical) PTEN copy number deletions and sensitivity to MK-2206 and rapamycin in osteosarcoma.
  • (Preclinical) RB1 somatic variants and sensitivity to olaparib and palbociclib in osteosarcoma.
  • (Preclinical) TP53 copy number deletions and sensitivity to talazoparib in osteosarcoma.
  • (Preclinical) TP53 somatic variants and sensitivity to NSC59984 in osteosarcoma.
  Continue reading
• Database release 2023-09-07 Categories:  Database, Release

  Added entries:

  • (FDA) BRCA1 somatic and germline variants and sensitivity to abiraterone acetate in combination with niraparib for patients with metastatic castration-resistant prostate cancer.
  • (FDA) BRCA2 somatic and germline variants and sensitivity to abiraterone acetate in combination with niraparib for patients with metastatic castration-resistant prostate cancer.
  • (FDA) MSI-H and sensitivity to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, in endometrial cancer.
  Continue reading
• Database release 2023-07-06 Categories:  Database, Release

  Added entries:

  • (FDA) BRCA1 and BRCA2 somatic and germline variants and sensitivity to olaparib in combination with abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer.
  • (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib for patients with metastatic pancreatic adenocarcinoma.
  • (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib for the treatment of adult patients with HER2-negative high risk early breast cancer.
  • (FDA) ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C somatic variants and sensitivity to talazoparib in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer.
  Continue reading